INfusion VErsus STimulation in Parkinson's Disease
- Conditions
- Parkinson's Disease
- Interventions
- Drug: Continuous intrajejunal infusion of levodopa-carbidopaDevice: deep brain stimulation
- Registration Number
- NCT02480803
- Brief Summary
Both Continuous intrajejunal Levodopa Infusion (CLI) and Deep Brain Stimulation (DBS) are accepted therapies for the treatment of advanced Parkinson's disease (PD). To date, no comparative studies have been executed. The INVEST study is an open label randomised controlled trial with cost-effectiveness as primary outcome. The main clinical outcome is quality of life; secondary outcomes are motor symptoms and neurological impairments, among others.
- Detailed Description
Rationale: Both Continuous intrajejunal Levodopa Infusion (CLI) and Deep Brain Stimulation (DBS) are accepted therapies for the treatment of advanced Parkinson's disease (PD). As directly comparative studies are lacking, it is unknown whether one of the therapies is more effective. Besides, CLI seems to be more expensive. To determine the optimal treatment in advanced PD, a comparative study of CLI and DBS is warranted.
Hypothesis: We hypothesize that CLI is a more expensive therapy in advanced PD than DBS and that the surplus in costs is not cost-effective with regard to benefits for the patient and caregivers in quality of life, PD symptoms and adverse events.
Objective: To realize a cost-effective treatment strategy in advanced PD. Study design: Prospective, randomized, open label multicentre trial, with two additional patient preference treatment arms ("patient preference randomized trial").
Study population: Patients with PD who, despite optimal pharmacological treatment, have severe response fluctuations, dyskinesias, painful dystonia, or bradykinesia. A total of 66 patients will be randomized, at least 120 patients will be included in the patient preference arms.
Intervention: Patients will be randomized to DBS or CLI. For DBS treatment, 2 electrodes will be implanted in the brain. The electrodes are connected to an implanted pulse generator, which will be placed subcutaneously in the subclavian area. For CLI treatment, a tube will be placed in the jejunum via a percutaneous endoscopic gastrostomy (PEG). This tube is connected to an external pump that delivers the levodopa-gel.
Main study parameters: There are 8 specified assessment visits: at baseline, and 1 week, 3, 6, 9, 12, 24 and 36 months after start of the study treatment. The primary health economic outcomes are the costs per changed unit on the PDQ-39 (and the costs per changed QALY for the cost-effectiveness and cost-utility analyses, respectively. The EQ-5D will be applied as the utility measure. Change in quality of life (expressed in the between group difference in change from baseline to 12 months on the PDQ-39 summary index score) is the main clinical outcome. Among the secondary outcomes are functional health, complications and adverse effects, use of care and perceptions of patients and neurologists regarding both treatments.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 51
- Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry;
- Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia;
- A life expectancy of at least two years.
- Age below 18 years
- Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy);
- Previous CLI (through a PEG-tube or Nasal Jejuna| tube);
- Hoehn and Yahr stage 5 at the best moment during the day;
- Other severely disabling disease;
- Dementia or signs of severe cognitive impairment
- Psychosis;
- Current depression;
- Contraindications for DBS surgery, such as a physical disorder making surgery hazardous;
- Contraindications for PEG surgery such as interposed organs, ascites and oesophagogastric varices, or for Duodopa;
- Pregnancy, breastfeeding, and women of child bearing age not using a reliable method of contraception;
- No informed consent;
- Legally incompetent adults;
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description continuous levodopa infusion Continuous intrajejunal infusion of levodopa-carbidopa continuous intrajejunal infusion of levodopa-carbidopa deep brain stimulation deep brain stimulation Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
- Primary Outcome Measures
Name Time Method Cost effectiveness in costs per changed unit on PDQ-39 12 months The costs per changed unit on the PDQ-39.
Cost-utility in costs per changed Quality Adjusted Life Year (QALY, years) 12 months The costs per QALY. The EuroQol 5D-3L (EQ-5D; 5 questions, each score 1-3, providing a health state, to be translated with provided Valuation set) will be applied as the utility measure.
- Secondary Outcome Measures
Name Time Method Quality of life (on PDQ-39) 12, 24 and 36 months Changes from Baseline on Parkinson's Disease Questionnaire-39 (PDQ-39; score 0-100, higher score is lower quality of life)
Dyskinesia 12 and 36 months Change from Baseline on clinical Dyskinesia Rating Scale (CDRS; score 0-28, high score is more dyskinesia)
Neuropsychologic functioning Clock 12 and 36 months Change from Baseline in Clock construction (score 0-14, higher is better)
Psychiatric disease 12 and 36 months Change from Baseline in Mini International Neuropsychiatric Interview
Anxiety 12 and 36 months Changes from Baseline on Hamilton Anxiety Scale (HAM-A; 0-56, high score is worse outcome)
Adverse effects 12, 24 and 36 months Number of participants with adverse effects and description of these
Patient satisfaction 12, 24 and 36 months Descriptive questionnaire, no scale applied, descriptive statistics
Patients attitude to treatment 12, 24 and 36 months Change from Baseline on Patient Reported Outcome Scale (range 0-128, high score is worse outcome)
Medical costs 12, 24 and 36 months Calculation of the total costs in euro by means of iMCQ (iMTA Medical Consumption Questionnaire)
Non-medical care costs 12, 24 and 36 months Calculation of the total costs in euro by means of iPCQ (iMTA Productivity Cost Questionnaire)
Caregiver burden 12, 24 and 36 months Descriptive questionnaire, no scale applied, descriptive statistics
Motor symptoms: time in off and on-state 12, 24 and 36 months Change from Baseline in time in off-state, on-state without dyskinesias, on-state without troublesome dyskinesias and on-state with troublesome dyskinesias measured with motor symptom diary
Motor experiences of daily living 12, 24 and 36 months Changes from Baseline on MDS-UPDRS part 2 (Movement Disorder Society's Unified Parkinson Disease Rating Scale (MDS-UPDRS part 2; score 0-52, high score is more worse health)
Non-motor symptoms (Non Motor Symptom Checklist) 12, 24 and 36 months Changes from Baseline on Non Motor Symptom Checklist
Non-motor symptoms (SCOPA-AUT) 12, 24 and 36 months Change from Baseline on SCOPA-AUT (SCales for Outcomes in PArkinson's Autonomic symptoms; score 0-92, higher score is more symptoms)
Disability 12, 24 and 36 months Change from Baseline in Hoehn and Yahr stage (H\&Y stage; 1-5: a higher score is more disease progression)
Cognitive functioning 12 and 36 months Change from Baseline on Parkinson's Disease Cognition Rating Scale (PD-CRS; 0-134, higher score is a result of better cognitive performance)
Cognitive functioning Mattis 12 and 36 months Change from Baseline in Mattis Dementia Rating score (score 0-144, higher score is better cognitive function)
Neuropsychologic functioning WAIS IV 12 and 36 months Change from Baseline in WAIS IV (Wechsler Adult Intelligence Scale IV - subsection similarities; score 0-36, higher is better)
Neuropsychologic functioning Word Test 12 and 36 months Change from Baseline in 15 word test (0-75, higher is better)
Neuropsychologic functioning Trail making 12 and 36 months Change from Baseline in Trail making test (score 10-500, higher score is longer time, i.e. worse score)
Non-motor symptoms (Rotterdam Symptom Checklist 12, 24 and 36 months Change from Baseline on Rotterdam Symptom Checklist
Neuropsychologic functioning Letter Fluency 12 and 36 months Change from Baseline in Letter Fluency (score 0-100, higher is better)
Neuropsychologic functioning Color Word 12 and 36 months Change from Baseline in Stroop Color Word Test (score 10-1000, higher is better)
Suicidality 12 and 36 months Changes from Baseline on Columbia Suicide Severity Rating Scale (range 0-25, higher score is worse outcome)
Treatment cross-over 12, 24 and 36 months Number of participants with treatment cross-over
Quality of life (on EQ-5D) 12, 24 and 36 months Change from Baseline on EuroQol 5D-3L (EQ-5D; 5 questions, each score 1-3, providing a health state, to be translated with provided Valuation set)
Neuropsychologic functioning Reading 12 and 36 months Change from Baseline in Dutch Reading Test (0-100, higher is better)
Neuropsychologic functioning Memory 12 and 36 months Change from Baseline in Rivermead Behavioral memory test (subsection stores; score 0-42, higher is better)
Motor symptoms 12 and 36 months Score changes from Baseline in off and on state on Movement Disorder Society's Unified Parkinson Disease Rating Scale (MDS-UPDRS part 3; 0-132, high score is more motor symptoms)
PD-medication (levodopa-equivalent dose) 12, 24 and 36 months Change from Baseline expressed in levodopa-equivalent dose
Functional health status 12, 24 and 36 months Change from Baseline on Amsterdam Linear Disability Score (ALDS, 29 items; 0-100, high score is high level of functional status)
Neuropsychologic functioning BNT 12 and 36 months Change from Baseline in Boston Naming Test (range 0-30, higher is better)
Neuropsychologic functioning Line Orientation 12 and 36 months Change from Baseline in Judgement of line orientation (score 0-30, higher is better)
Apathy 12, 24 and 36 months Change from Baseline in Starkstein's Apathy Scale (SAS; score 0-42, high score is more signs of apathy)
Compulsive Disorders 12, 24 and 36 months Change in presence of Compulsive Disorder from Baseline assessed with Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire (QUIP, utilizing established thresholds)
Depression 12 and 36 months Change from Baseline on Hamilton Depression Rating Scale (HDRS; 0-68, higher score is worse outcome)
Complications and description of complications 12, 24 and 36 months Number of participants with complications and description of these
Stopping allocated treatment 12, 24 and 36 months Number of participants who stopped treatment
Treatment failure 12, 24 and 36 months Number of participants with treatment failure
Trial Locations
- Locations (1)
Academic Medical Center
🇳🇱Amsterdam, Noord Holland, Netherlands